Emmessar Biotech & Nutrition Limited has announced its financial results for the quarter ended June 30, 2025, following approval by its Board of Directors.

For the quarter, the company reported revenue from operations of Rs 0.23 Cr and a net loss of Rs 0.28 Cr.

Basic and diluted earnings per share stood at Rs (0.13). These unaudited results underwent a limited review by statutory auditors, offering shareholders a timely overview of the company's recent financial performance.